Evidence supporting the role of AhR in lung physiology, including negative NLRP3 regulation [69], could provide new COVID-19 therapeutic opportunities based on the AhR and/or other xenobiotic receptor biological functions (Figure 1). The gene discussed is NLRP3; the disease is COVID-19.